IMMEDIATE-RELEASE NIFEDIPINE LABELING WILL WARN AGAINST OFF-LABEL USES, FDA INDICATES FOLLOWING CALCIUM CHANNEL BLOCKER ADVISORY COMMITTEE REVIEW
Executive Summary
Immediate-release nifedipine product labeling will be changed to warn of potential safety problems with off-label use in hypertension and other conditions, FDA said following the Cardiovascular & Renal Drugs Advisory Committee review of calcium channel blocker safety concerns Jan. 25.
You may also be interested in...
ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs
The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011